Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia
The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype Pseudomonas aeruginosa infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosoc...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2014-10, Vol.33 (10), p.1861-1867 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1867 |
|---|---|
| container_issue | 10 |
| container_start_page | 1861 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 33 |
| creator | Que, Y.-A. Lazar, H. Wolff, M. François, B. Laterre, P.-F. Mercier, E. Garbino, J. Pagani, J.-L. Revelly, J.-P. Mus, E. Perez, A. Tamm, M. Rouby, J.-J. Lu, Q. Chastre, J. Eggimann, P. |
| description | The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype
Pseudomonas aeruginosa
infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosocomial pneumonia. We performed a post-hoc analysis of a multicenter phase IIa trial (NCT00851435) designed to prospectively evaluate the safety and pharmacokinetics of panobacumab. Patients treated with panobacumab (
n
= 17), including 13 patients receiving the full treatment (three doses of 1.2 mg/kg), were compared to 14 patients who did not receive the antibody. Overall, the 17 patients receiving panobacumab were more ill. They were an average of 72 years old [interquartile range (IQR): 64–79] versus an average of 50 years old (IQR: 30–73) (
p
= 0.024) and had Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of 17 (IQR: 16–22) versus 15 (IQR: 10–19) (
p
= 0.043). Adjunctive immunotherapy resulted in an improved clinical outcome in the group receiving the full three-course panobacumab treatment, with a resolution rate of 85 % (11/13) versus 64 % (9/14) (
p
= 0.048). The Kaplan–Meier survival curve showed a statistically significantly shorter time to clinical resolution in this group of patients (8.0 [IQR: 7.0–11.5] versus 18.5 [IQR: 8–30] days in those who did not receive the antibody;
p
= 0.004). Panobacumab adjunctive immunotherapy may improve clinical outcome in a shorter time if patients receive the full treatment (three doses). These preliminary results suggest that passive immunotherapy targeting LPS may be a complementary strategy for the treatment of nosocomial O11
P. aeruginosa
pneumonia. |
| doi_str_mv | 10.1007/s10096-014-2156-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1618150542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3448905611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-f48f0c85e03c0cdeb8ec87e4fadeae34ef250bdead2a2e65c6ec9049e6b081243</originalsourceid><addsrcrecordid>eNp1kV-L1TAQxYMo7t3VD-CLBETYl2rSJm36uCz-gwV90OcwTadrL01SM83CfntzvXdVBF-SIfM7J5Mcxl5I8UYK0b2lsvZtJaSqaqnbSj5iO6kaXammax6znegbVfVd3Zyxc6K9KBrTdU_ZWa2M7nvR7djdFRESeQwbjxNfIcQBXPYwcCAO4z4Ht813yGfvc4jbd0yw3vMpJl5qviWE7UEcIkUX_QwL_0KYx-hjOJhgyrdzaQJfA-ZyOMMz9mSChfD5ab9g396_-3r9sbr5_OHT9dVN5bQyWzUpMwlnNIrGCTfiYNCZDtUEIwI2Cqdai6HUYw01ttq16HqhemwHYWStmgt2efRdU_yRkTbrZ3K4LBAwZrKylUZqoVVd0Ff_oPuYUyjT2fK3bdcUqC-UPFIuRaKEk13T7CHdWynsIRR7DMWWUOwhFCuL5uXJOQ8ex9-KhxQK8PoEADlYpgTBzfSHM6YX-tdr6iNHpRVuMf014n9v_wlkvKeW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1566735429</pqid></control><display><type>article</type><title>Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Que, Y.-A. ; Lazar, H. ; Wolff, M. ; François, B. ; Laterre, P.-F. ; Mercier, E. ; Garbino, J. ; Pagani, J.-L. ; Revelly, J.-P. ; Mus, E. ; Perez, A. ; Tamm, M. ; Rouby, J.-J. ; Lu, Q. ; Chastre, J. ; Eggimann, P.</creator><creatorcontrib>Que, Y.-A. ; Lazar, H. ; Wolff, M. ; François, B. ; Laterre, P.-F. ; Mercier, E. ; Garbino, J. ; Pagani, J.-L. ; Revelly, J.-P. ; Mus, E. ; Perez, A. ; Tamm, M. ; Rouby, J.-J. ; Lu, Q. ; Chastre, J. ; Eggimann, P.</creatorcontrib><description>The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype
Pseudomonas aeruginosa
infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosocomial pneumonia. We performed a post-hoc analysis of a multicenter phase IIa trial (NCT00851435) designed to prospectively evaluate the safety and pharmacokinetics of panobacumab. Patients treated with panobacumab (
n
= 17), including 13 patients receiving the full treatment (three doses of 1.2 mg/kg), were compared to 14 patients who did not receive the antibody. Overall, the 17 patients receiving panobacumab were more ill. They were an average of 72 years old [interquartile range (IQR): 64–79] versus an average of 50 years old (IQR: 30–73) (
p
= 0.024) and had Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of 17 (IQR: 16–22) versus 15 (IQR: 10–19) (
p
= 0.043). Adjunctive immunotherapy resulted in an improved clinical outcome in the group receiving the full three-course panobacumab treatment, with a resolution rate of 85 % (11/13) versus 64 % (9/14) (
p
= 0.048). The Kaplan–Meier survival curve showed a statistically significantly shorter time to clinical resolution in this group of patients (8.0 [IQR: 7.0–11.5] versus 18.5 [IQR: 8–30] days in those who did not receive the antibody;
p
= 0.004). Panobacumab adjunctive immunotherapy may improve clinical outcome in a shorter time if patients receive the full treatment (three doses). These preliminary results suggest that passive immunotherapy targeting LPS may be a complementary strategy for the treatment of nosocomial O11
P. aeruginosa
pneumonia.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-014-2156-1</identifier><identifier>PMID: 24859907</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Antibodies, Bacterial - administration & dosage ; Antibodies, Bacterial - adverse effects ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - pharmacokinetics ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cross Infection - microbiology ; Cross Infection - therapy ; Drug dosages ; Female ; General aspects ; Gram-negative bacteria ; Human infectious diseases. Experimental studies and models ; Humans ; Immunoglobulin M - administration & dosage ; Immunoglobulin M - adverse effects ; Immunologic Factors - administration & dosage ; Immunologic Factors - adverse effects ; Immunologic Factors - pharmacokinetics ; Immunotherapy ; Immunotherapy - methods ; Infectious diseases ; Internal Medicine ; Male ; Medical Microbiology ; Medical sciences ; Middle Aged ; Monoclonal antibodies ; Mortality ; Nosocomial infection ; Nosocomial infections ; Pharmacokinetics ; Physiology ; Pneumology ; Pneumonia ; Pneumonia, Bacterial - microbiology ; Pneumonia, Bacterial - therapy ; Prospective Studies ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - classification ; Pseudomonas aeruginosa - immunology ; Respiratory system : syndromes and miscellaneous diseases ; Sepsis ; Serogroup ; Treatment Outcome ; Virulence</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2014-10, Vol.33 (10), p.1861-1867</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548t-f48f0c85e03c0cdeb8ec87e4fadeae34ef250bdead2a2e65c6ec9049e6b081243</citedby><cites>FETCH-LOGICAL-c548t-f48f0c85e03c0cdeb8ec87e4fadeae34ef250bdead2a2e65c6ec9049e6b081243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-014-2156-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-014-2156-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28890524$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24859907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Que, Y.-A.</creatorcontrib><creatorcontrib>Lazar, H.</creatorcontrib><creatorcontrib>Wolff, M.</creatorcontrib><creatorcontrib>François, B.</creatorcontrib><creatorcontrib>Laterre, P.-F.</creatorcontrib><creatorcontrib>Mercier, E.</creatorcontrib><creatorcontrib>Garbino, J.</creatorcontrib><creatorcontrib>Pagani, J.-L.</creatorcontrib><creatorcontrib>Revelly, J.-P.</creatorcontrib><creatorcontrib>Mus, E.</creatorcontrib><creatorcontrib>Perez, A.</creatorcontrib><creatorcontrib>Tamm, M.</creatorcontrib><creatorcontrib>Rouby, J.-J.</creatorcontrib><creatorcontrib>Lu, Q.</creatorcontrib><creatorcontrib>Chastre, J.</creatorcontrib><creatorcontrib>Eggimann, P.</creatorcontrib><title>Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype
Pseudomonas aeruginosa
infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosocomial pneumonia. We performed a post-hoc analysis of a multicenter phase IIa trial (NCT00851435) designed to prospectively evaluate the safety and pharmacokinetics of panobacumab. Patients treated with panobacumab (
n
= 17), including 13 patients receiving the full treatment (three doses of 1.2 mg/kg), were compared to 14 patients who did not receive the antibody. Overall, the 17 patients receiving panobacumab were more ill. They were an average of 72 years old [interquartile range (IQR): 64–79] versus an average of 50 years old (IQR: 30–73) (
p
= 0.024) and had Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of 17 (IQR: 16–22) versus 15 (IQR: 10–19) (
p
= 0.043). Adjunctive immunotherapy resulted in an improved clinical outcome in the group receiving the full three-course panobacumab treatment, with a resolution rate of 85 % (11/13) versus 64 % (9/14) (
p
= 0.048). The Kaplan–Meier survival curve showed a statistically significantly shorter time to clinical resolution in this group of patients (8.0 [IQR: 7.0–11.5] versus 18.5 [IQR: 8–30] days in those who did not receive the antibody;
p
= 0.004). Panobacumab adjunctive immunotherapy may improve clinical outcome in a shorter time if patients receive the full treatment (three doses). These preliminary results suggest that passive immunotherapy targeting LPS may be a complementary strategy for the treatment of nosocomial O11
P. aeruginosa
pneumonia.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Bacterial - administration & dosage</subject><subject>Antibodies, Bacterial - adverse effects</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cross Infection - microbiology</subject><subject>Cross Infection - therapy</subject><subject>Drug dosages</subject><subject>Female</subject><subject>General aspects</subject><subject>Gram-negative bacteria</subject><subject>Human infectious diseases. Experimental studies and models</subject><subject>Humans</subject><subject>Immunoglobulin M - administration & dosage</subject><subject>Immunoglobulin M - adverse effects</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunologic Factors - adverse effects</subject><subject>Immunologic Factors - pharmacokinetics</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Nosocomial infection</subject><subject>Nosocomial infections</subject><subject>Pharmacokinetics</subject><subject>Physiology</subject><subject>Pneumology</subject><subject>Pneumonia</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Pneumonia, Bacterial - therapy</subject><subject>Prospective Studies</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - classification</subject><subject>Pseudomonas aeruginosa - immunology</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><subject>Sepsis</subject><subject>Serogroup</subject><subject>Treatment Outcome</subject><subject>Virulence</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kV-L1TAQxYMo7t3VD-CLBETYl2rSJm36uCz-gwV90OcwTadrL01SM83CfntzvXdVBF-SIfM7J5Mcxl5I8UYK0b2lsvZtJaSqaqnbSj5iO6kaXammax6znegbVfVd3Zyxc6K9KBrTdU_ZWa2M7nvR7djdFRESeQwbjxNfIcQBXPYwcCAO4z4Ht813yGfvc4jbd0yw3vMpJl5qviWE7UEcIkUX_QwL_0KYx-hjOJhgyrdzaQJfA-ZyOMMz9mSChfD5ab9g396_-3r9sbr5_OHT9dVN5bQyWzUpMwlnNIrGCTfiYNCZDtUEIwI2Cqdai6HUYw01ttq16HqhemwHYWStmgt2efRdU_yRkTbrZ3K4LBAwZrKylUZqoVVd0Ff_oPuYUyjT2fK3bdcUqC-UPFIuRaKEk13T7CHdWynsIRR7DMWWUOwhFCuL5uXJOQ8ex9-KhxQK8PoEADlYpgTBzfSHM6YX-tdr6iNHpRVuMf014n9v_wlkvKeW</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Que, Y.-A.</creator><creator>Lazar, H.</creator><creator>Wolff, M.</creator><creator>François, B.</creator><creator>Laterre, P.-F.</creator><creator>Mercier, E.</creator><creator>Garbino, J.</creator><creator>Pagani, J.-L.</creator><creator>Revelly, J.-P.</creator><creator>Mus, E.</creator><creator>Perez, A.</creator><creator>Tamm, M.</creator><creator>Rouby, J.-J.</creator><creator>Lu, Q.</creator><creator>Chastre, J.</creator><creator>Eggimann, P.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T5</scope></search><sort><creationdate>20141001</creationdate><title>Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia</title><author>Que, Y.-A. ; Lazar, H. ; Wolff, M. ; François, B. ; Laterre, P.-F. ; Mercier, E. ; Garbino, J. ; Pagani, J.-L. ; Revelly, J.-P. ; Mus, E. ; Perez, A. ; Tamm, M. ; Rouby, J.-J. ; Lu, Q. ; Chastre, J. ; Eggimann, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-f48f0c85e03c0cdeb8ec87e4fadeae34ef250bdead2a2e65c6ec9049e6b081243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Bacterial - administration & dosage</topic><topic>Antibodies, Bacterial - adverse effects</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cross Infection - microbiology</topic><topic>Cross Infection - therapy</topic><topic>Drug dosages</topic><topic>Female</topic><topic>General aspects</topic><topic>Gram-negative bacteria</topic><topic>Human infectious diseases. Experimental studies and models</topic><topic>Humans</topic><topic>Immunoglobulin M - administration & dosage</topic><topic>Immunoglobulin M - adverse effects</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunologic Factors - adverse effects</topic><topic>Immunologic Factors - pharmacokinetics</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Nosocomial infection</topic><topic>Nosocomial infections</topic><topic>Pharmacokinetics</topic><topic>Physiology</topic><topic>Pneumology</topic><topic>Pneumonia</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Pneumonia, Bacterial - therapy</topic><topic>Prospective Studies</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - classification</topic><topic>Pseudomonas aeruginosa - immunology</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><topic>Sepsis</topic><topic>Serogroup</topic><topic>Treatment Outcome</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Que, Y.-A.</creatorcontrib><creatorcontrib>Lazar, H.</creatorcontrib><creatorcontrib>Wolff, M.</creatorcontrib><creatorcontrib>François, B.</creatorcontrib><creatorcontrib>Laterre, P.-F.</creatorcontrib><creatorcontrib>Mercier, E.</creatorcontrib><creatorcontrib>Garbino, J.</creatorcontrib><creatorcontrib>Pagani, J.-L.</creatorcontrib><creatorcontrib>Revelly, J.-P.</creatorcontrib><creatorcontrib>Mus, E.</creatorcontrib><creatorcontrib>Perez, A.</creatorcontrib><creatorcontrib>Tamm, M.</creatorcontrib><creatorcontrib>Rouby, J.-J.</creatorcontrib><creatorcontrib>Lu, Q.</creatorcontrib><creatorcontrib>Chastre, J.</creatorcontrib><creatorcontrib>Eggimann, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Immunology Abstracts</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Que, Y.-A.</au><au>Lazar, H.</au><au>Wolff, M.</au><au>François, B.</au><au>Laterre, P.-F.</au><au>Mercier, E.</au><au>Garbino, J.</au><au>Pagani, J.-L.</au><au>Revelly, J.-P.</au><au>Mus, E.</au><au>Perez, A.</au><au>Tamm, M.</au><au>Rouby, J.-J.</au><au>Lu, Q.</au><au>Chastre, J.</au><au>Eggimann, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>33</volume><issue>10</issue><spage>1861</spage><epage>1867</epage><pages>1861-1867</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype
Pseudomonas aeruginosa
infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosocomial pneumonia. We performed a post-hoc analysis of a multicenter phase IIa trial (NCT00851435) designed to prospectively evaluate the safety and pharmacokinetics of panobacumab. Patients treated with panobacumab (
n
= 17), including 13 patients receiving the full treatment (three doses of 1.2 mg/kg), were compared to 14 patients who did not receive the antibody. Overall, the 17 patients receiving panobacumab were more ill. They were an average of 72 years old [interquartile range (IQR): 64–79] versus an average of 50 years old (IQR: 30–73) (
p
= 0.024) and had Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of 17 (IQR: 16–22) versus 15 (IQR: 10–19) (
p
= 0.043). Adjunctive immunotherapy resulted in an improved clinical outcome in the group receiving the full three-course panobacumab treatment, with a resolution rate of 85 % (11/13) versus 64 % (9/14) (
p
= 0.048). The Kaplan–Meier survival curve showed a statistically significantly shorter time to clinical resolution in this group of patients (8.0 [IQR: 7.0–11.5] versus 18.5 [IQR: 8–30] days in those who did not receive the antibody;
p
= 0.004). Panobacumab adjunctive immunotherapy may improve clinical outcome in a shorter time if patients receive the full treatment (three doses). These preliminary results suggest that passive immunotherapy targeting LPS may be a complementary strategy for the treatment of nosocomial O11
P. aeruginosa
pneumonia.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24859907</pmid><doi>10.1007/s10096-014-2156-1</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2014-10, Vol.33 (10), p.1861-1867 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1618150542 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antibodies, Bacterial - administration & dosage Antibodies, Bacterial - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Biological and medical sciences Biomedical and Life Sciences Biomedicine Cross Infection - microbiology Cross Infection - therapy Drug dosages Female General aspects Gram-negative bacteria Human infectious diseases. Experimental studies and models Humans Immunoglobulin M - administration & dosage Immunoglobulin M - adverse effects Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - pharmacokinetics Immunotherapy Immunotherapy - methods Infectious diseases Internal Medicine Male Medical Microbiology Medical sciences Middle Aged Monoclonal antibodies Mortality Nosocomial infection Nosocomial infections Pharmacokinetics Physiology Pneumology Pneumonia Pneumonia, Bacterial - microbiology Pneumonia, Bacterial - therapy Prospective Studies Pseudomonas aeruginosa Pseudomonas aeruginosa - classification Pseudomonas aeruginosa - immunology Respiratory system : syndromes and miscellaneous diseases Sepsis Serogroup Treatment Outcome Virulence |
| title | Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20panobacumab%20as%20adjunctive%20immunotherapy%20for%20the%20treatment%20of%20nosocomial%20Pseudomonas%20aeruginosa%20pneumonia&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Que,%20Y.-A.&rft.date=2014-10-01&rft.volume=33&rft.issue=10&rft.spage=1861&rft.epage=1867&rft.pages=1861-1867&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-014-2156-1&rft_dat=%3Cproquest_cross%3E3448905611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1566735429&rft_id=info:pmid/24859907&rfr_iscdi=true |